首页> 外文期刊>The Journal of Urology >A critical assessment of post-prostatectomy prostate specific antigen doubling time acceleration - Is it stable?
【24h】

A critical assessment of post-prostatectomy prostate specific antigen doubling time acceleration - Is it stable?

机译:前列腺切除术后前列腺特异性抗原加倍时间加速的关键评估-是否稳定?

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose: We examined a retrospective cohort of patients with biochemical recurrence after prostatectomy to determine whether prostate specific antigen doubling time would remain stable with time. We also examined the relationship between other clinical parameters and the change in prostate specific antigen doubling time. Materials and Methods: We retrospectively reviewed the prostate cancer database from 1989 to 2008 to identify patients treated with radical prostatectomy for prostate cancer who experienced prostate specific antigen recurrence. Of the 2,237 patients identified 329 had biochemical recurrence. Prostate specific antigen doubling time was calculated at each visit and linear regression of prostate specific antigen doubling time with time was fit. Rate of change in prostate specific antigen doubling time was defined as the slope of the least squares regression line. Results: Median followup was 5 years (range 0.2 to 18). High Gleason score and local recurrence within 5 years were significantly associated with shorter 2-year prostate specific antigen doubling time and a decreased rate of change in doubling time (p = 0.0096, 0.0119, 0.0195 and 0.0258, respectively). Metastasis within 5 years was significantly associated with shorter 2 and 5-year doubling time (p = 0.0006 and 0.0014, respectively). Using all prostate specific antigen values within 5 years of initial biochemical recurrence yielded an overall median prostate specific antigen doubling time of 52.8 months (range 5.4 to 100.0). The median rate of change in doubling time was -1.05 (range -64.7 to 27.0). Median time to metastasis after biochemical recurrence was 12.9 years. Conclusions: Median prostate specific antigen doubling time decreases with time. This may influence the decision to offer secondary therapy to patients with biochemical recurrence sooner since initial prostate specific antigen doubling time is long and may not accurately reflect the biological nature of the disease.
机译:目的:我们回顾性分析了前列腺切除术后生化复发患者的回顾性队列研究,以确定前列腺特异性抗原加倍时间是否会随时间保持稳定。我们还检查了其他临床参数与前列腺特异性抗原加倍时间变化之间的关系。材料和方法:我们回顾性分析了1989年至2008年的前列腺癌数据库,以鉴定接受前列腺癌根治性前列腺切除术治疗的患者,这些患者经历了前列腺特异性抗原复发。在确定的2237例患者中,有329例发生了生化复发。在每次就诊时计算前列腺特异性抗原加倍时间,并且拟合前列腺特异性抗原加倍时间随时间的线性回归。前列腺特异性抗原加倍时间的变化率定义为最小二乘回归线的斜率。结果:中位随访时间为5年(范围0.2到18)。高格里森评分和5年内局部复发与2年较短的前列腺特异性抗原加倍时间和加倍时间变化率降低显着相关(分别为p = 0.0096、0.0119、0.0195和0.0258)。 5年内的转移与2年和5年的倍增时间缩短显着相关(分别为p = 0.0006和0.0014)。在初始生化复发的5年内使用所有前列腺特异性抗原值,得出的总体中位前列腺特异性抗原加倍时间为52.8个月(范围为5.4至100.0)。倍增时间的中位数变化率为-1.05(范围为-64.7至27.0)。生化复发后转移的中位时间为12.9年。结论:中位前列腺特异性抗原加倍时间随时间减少。由于最初的前列腺特异性抗原加倍时间长且可能无法准确反映疾病的生物学性质,因此这可能会影响为生化复发的患者提供二次治疗的决定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号